Skip to main content

Published locations for High-risk HR+/HER2− early BC: Higher pCR rate with neoadjuvant nab-paclitaxel vs dose-dense solvent-based paclitaxel

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. High-risk HR+/HER2− early BC: Higher pCR rate with neoadjuvant nab-paclitaxel vs dose-dense solvent-based paclitaxel

User login

  • Reset your password
  • /content/high-risk-hr/her2-early-bc-higher-pcr-rate-neoadjuvant-nab-paclitaxel-vs-dose-dense-solvent
  • /breast-cancer-icymi/article/263001/breast-cancer/high-risk-hr/her2-early-bc-higher-pcr-rate